The influence of parecoxib: A parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam

Anesthesia and Analgesia

Volumn 95, Issue 3, 2002, Pages 667-673

  Ibrahim, Andra ^a   Karim, Aziz ^a   Feldman, Jennifer ^a   Kharasch, Evan ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; MIDAZOLAM; PARECOXIB; VALDECOXIB;

ADULT; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

EID: 0036711878     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-200209000-00032     Document Type: Article

References (25)

1. Evaluation of intravenous parecoxib for the relief of acute post-surgical pain
2. N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration
3. A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model
4. A comparative analgesic efficacy study of parecoxib sodium, a new injectable COX-2 specific inhibitor, in post-orthopedic surgery patients
5. Analgesic activity and safety of parecoxib in post-surgical patients: An interim report
6. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo
7. Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals
8. A potentially hazardous interaction between erythromycin and midazolam
9. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole
10. The role of cytochrome P450 3A4 in alfentanil clearance
11. In vitro and in vivo drug interactions involving human CYP3A
12. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
13. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
14. Use of midazolam as a human cytochrome P450 3A probe. I. In vitro-in vivo correlations in liver transplant patients
15. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam
16. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance
17. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration
18. What do adult age differences in the digit symbol substitution test reflect?
19. Concreteness, imagery, and meaningfulness values for 925 nouns
20. Measures of free recall of 900 English nouns: Correlation with imagery concreteness, meaningfulness, and frequency
21. A pharmacokinetic study of intramuscular (IM) parecoxib sodium in normal subjects
22. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2
23. Physiologic and temporal variation in hepatic elimination of midazolam
24. Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam